Evotec 566480, wohin geht die Reise??? (Seite 8199)
eröffnet am 12.01.07 11:23:52 von
neuester Beitrag 31.05.24 17:14:47 von
neuester Beitrag 31.05.24 17:14:47 von
Beiträge: 82.416
ID: 1.104.790
ID: 1.104.790
Aufrufe heute: 7.397
Gesamt: 16.341.143
Gesamt: 16.341.143
Aktive User: 0
ISIN: DE0005664809 · WKN: 566480
8,6525
EUR
+2,49 %
+0,2100 EUR
Letzter Kurs 22:59:44 Lang & Schwarz
Neuigkeiten
| TitelBeiträge |
|---|
29.05.24 · wallstreetONLINE Redaktion |
| Evotec Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!Anzeige |
19:00 Uhr · Felix Haupt Anzeige |
17:50 Uhr · wO Newsflash |
Chartanalyse: Evotec im Tal der Tränen: Neue Mehrjahrestiefs voraus?Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,4000 | +70,89 | |
| 3,3000 | +36,93 | |
| 6,8500 | +31,48 | |
| 2,6399 | +30,69 | |
| 4,9500 | +28,57 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,4800 | -17,80 | |
| 9,6000 | -18,64 | |
| 8,6850 | -20,47 | |
| 2,0400 | -58,87 | |
| 0,8020 | -91,06 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 29.426.877 von Ruppi am 22.05.07 22:42:30So Jungs könnt ihr bitte mal ein paar Pakete abladen?
Danke!
Danke!
Antwort auf Beitrag Nr.: 29.332.615 von bolero6 am 15.05.07 20:26:25Anscheinend beflügeln die Neuigkeiten von GPC Biotech auch Evotec, Die Phase 2 Daten die im Juni kommen zur Abwechslung auch mal Positiv sein könnten.
GPC Biotech:
22.05 09:27
GPC Biotech mit guten Neuigkeiten!
Unser Musterdepotwert GPC Biotech AG (WKN: 585150 / Kürzel: GPC) hat neue positive Studienergebnisse zum Krebsmedikament Satraplatin veröffentlicht. Demnach führt die Einnahme des Präparates zu einer 36prozentigen Verringerung der Verschlimmerung der Schmerzen bei Patienten mit hormonresistentem Prostatakrebs, wodurch das Medikament neben der oralen Einnahme über einen weiteren Wettbewerbsvorteil gegenüber der Konkurrenz verfügt. Damit konnte das Unternehmen einen weiteren Erfolg im Rahmen der Phase-3-Zulassungsstudie SPARC erreichen. Ein positiver Entscheid der Zulassungsbehörde FDA im August wird dadurch immer wahrscheinlicher. Auf dem aktuellen Niveau ist die Aktie noch günstig zu haben. Sollte Satraplatin im August für den amerikanischen Markt zugelassen werden, könnte sich das Medikament zu einem wahren Pharma-Blockbuster entwickeln.
Nur mit dem Unterschied das bei GPC Biotech erst im August die Ergebnisse bringt und Evotec schon in max. 4 Wochen.
10.05.2007 - 09:46 Uhr
Evotec will am Quartalsende neue Daten zu Schlafmittel vorlegen
DÜSSELDORF (Dow Jones)--Die Evotec AG rechnet früher als bisher geplant mit den wesentlichen Eckdaten einer Studie mit dem Medikamentenkandidaten EVT 201 gegen Schlafstörungen. Das Hamburger Biotechnologie-Unternehmen teilte am Donnerstag bei der Vorlage der Quartalszahlen mit, die Ergebnisse der Phase-II-Studie sollten Ende des zweiten Quartals veröffentlich werden. Bei einer zweiten Phase-II-Studie mit der Arznei sei die Rekrutierung von Patienten jedoch leicht verzögert. Hier werden Ergebnisse Ende dieses oder Anfang nächsten Jahres erwartet.
Werbung
Das operative Ergebnis des Unternehmens, das von seiner Mitarbeiter- und Umsatzzahl her zu den größten Biotechnologieunternehmen in Deutschland gehört und aufgrund der Forschung an Medikamenten unter anderem gegen Schlafstörungen, Alzheimer und zur Raucherentwöhnung im Blick der Branche steht, verbesserte sich in den Monaten Januar bis März leicht auf einen Verlust von 9 Mio EUR nach 9,1 Mio EUR in der Vorjahresperiode.
Der Umsatz fiel unter anderem aufgrund des starken Euro-Kurses jedoch auf 15,1 (15,8) Mio EUR. Zudem hatte im Vorjahreszeitraum eine Meilensteinzahlung aus der Kooperation mit dem Pharmakonzern Boehringer Ingelheim den Umsatz erhöht. 2007 werden derartige Meilensteinzahlungen erst später im Jahr erwartet. Das Nettoergebnis lag bei 2,7 Mio EUR nach einem Verlust von 8,8 Mio EUR vor Jahresfrist. Grund für die schwarze Zahl ist der Ertrag aus dem Verkauf des Geschäftsbereichs Evotec Technologies.
Webseite: http://www.evotec.de
GPC Biotech:
22.05 09:27
GPC Biotech mit guten Neuigkeiten!
Unser Musterdepotwert GPC Biotech AG (WKN: 585150 / Kürzel: GPC) hat neue positive Studienergebnisse zum Krebsmedikament Satraplatin veröffentlicht. Demnach führt die Einnahme des Präparates zu einer 36prozentigen Verringerung der Verschlimmerung der Schmerzen bei Patienten mit hormonresistentem Prostatakrebs, wodurch das Medikament neben der oralen Einnahme über einen weiteren Wettbewerbsvorteil gegenüber der Konkurrenz verfügt. Damit konnte das Unternehmen einen weiteren Erfolg im Rahmen der Phase-3-Zulassungsstudie SPARC erreichen. Ein positiver Entscheid der Zulassungsbehörde FDA im August wird dadurch immer wahrscheinlicher. Auf dem aktuellen Niveau ist die Aktie noch günstig zu haben. Sollte Satraplatin im August für den amerikanischen Markt zugelassen werden, könnte sich das Medikament zu einem wahren Pharma-Blockbuster entwickeln.
Nur mit dem Unterschied das bei GPC Biotech erst im August die Ergebnisse bringt und Evotec schon in max. 4 Wochen.
10.05.2007 - 09:46 Uhr
Evotec will am Quartalsende neue Daten zu Schlafmittel vorlegen
DÜSSELDORF (Dow Jones)--Die Evotec AG rechnet früher als bisher geplant mit den wesentlichen Eckdaten einer Studie mit dem Medikamentenkandidaten EVT 201 gegen Schlafstörungen. Das Hamburger Biotechnologie-Unternehmen teilte am Donnerstag bei der Vorlage der Quartalszahlen mit, die Ergebnisse der Phase-II-Studie sollten Ende des zweiten Quartals veröffentlich werden. Bei einer zweiten Phase-II-Studie mit der Arznei sei die Rekrutierung von Patienten jedoch leicht verzögert. Hier werden Ergebnisse Ende dieses oder Anfang nächsten Jahres erwartet.
Werbung
Das operative Ergebnis des Unternehmens, das von seiner Mitarbeiter- und Umsatzzahl her zu den größten Biotechnologieunternehmen in Deutschland gehört und aufgrund der Forschung an Medikamenten unter anderem gegen Schlafstörungen, Alzheimer und zur Raucherentwöhnung im Blick der Branche steht, verbesserte sich in den Monaten Januar bis März leicht auf einen Verlust von 9 Mio EUR nach 9,1 Mio EUR in der Vorjahresperiode.
Der Umsatz fiel unter anderem aufgrund des starken Euro-Kurses jedoch auf 15,1 (15,8) Mio EUR. Zudem hatte im Vorjahreszeitraum eine Meilensteinzahlung aus der Kooperation mit dem Pharmakonzern Boehringer Ingelheim den Umsatz erhöht. 2007 werden derartige Meilensteinzahlungen erst später im Jahr erwartet. Das Nettoergebnis lag bei 2,7 Mio EUR nach einem Verlust von 8,8 Mio EUR vor Jahresfrist. Grund für die schwarze Zahl ist der Ertrag aus dem Verkauf des Geschäftsbereichs Evotec Technologies.
Webseite: http://www.evotec.de
Am 30.5 ist die Hauptversammlung, biss dahin wird noch einiges Eingesammelt, damit mann auch ein Gewichtiges Mitsprache recht hat!
Trading Spotlight
Na gut!
Warten wir eben noch biss sich das Orderbuch auf der ASK seite ordentlich füllt und wenn dann immer noch niemand abgeladen hat, dann werden wir mit der Machete durch das ASK gehen.
Warten wir eben noch biss sich das Orderbuch auf der ASK seite ordentlich füllt und wenn dann immer noch niemand abgeladen hat, dann werden wir mit der Machete durch das ASK gehen.
Antwort auf Beitrag Nr.: 29.405.285 von peterm1973 am 21.05.07 16:25:40Biss die Ergebnisse von Phase 2 kommen sollte noch viel Bewegung in den Kurs kommen. Die folgenden 4 Wochen werden sehr Interessant werden.
Warum Verkauft eigentlich niemand mehr größere Pakete?
Bitte abladen!
Warum Verkauft eigentlich niemand mehr größere Pakete?
Bitte abladen!
Der Kurs bewegt sich!!!
Glaube nicht, dass es an der heutigen Meldung liegt, die war schon am Morgen publik. Der Kurs hat aber vor knapp einer Stunde begonnen nach oben zu gehen.
Wenn man das Orderbuch an der XETRA sieht weiss man auch wieso, da kauft jemand kräftig ein!!!
http://aktienkurs-orderbuch.finanznachrichten.de/evt.aspx
Komme bald die Ergebnisse aus Phase II?
Glaube nicht, dass es an der heutigen Meldung liegt, die war schon am Morgen publik. Der Kurs hat aber vor knapp einer Stunde begonnen nach oben zu gehen.
Wenn man das Orderbuch an der XETRA sieht weiss man auch wieso, da kauft jemand kräftig ein!!!
http://aktienkurs-orderbuch.finanznachrichten.de/evt.aspx
Komme bald die Ergebnisse aus Phase II?
21 May 2007
Evotec to Launch its First Innovation Centre for Fragment Based Drug Discovery
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the launch of its Innovation Centre for Fragment Based Drug Discovery ('FBDD'). FBDD offers an alternative approach for identifying novel, small molecule hits (fragments) for a number of biological targets including those that have proved problematic using traditional drug discovery methods as successfully demonstrated by companies such as Astex. Fragments, ideal starting points for rapid evolution to subsequent lead compounds due to their low molecular weight, are difficult to detect due to their weak interactions with protein targets. Evotec has implemented a unique and powerful fragment screening platform, EVOlution, capable of identifying low molecular weight fragments in a biologically relevant environment. The initial step is carried out using Evotec's ultra sensitive screening technologies and its library of 20,000 fragments designed and selected by its medicinal chemists. Combining this screening process with subsequent protein-ligand X-ray crystallography, Evotec's EVOlution technology can identify novel small molecule fragment hits for various, often difficult biological targets in a very short period of time. Leveraging its expertise in medicinal chemistry in combination with its fragment optimisation technology, Evotec can than rapidly progress the fragment programmes to identify novel lead structures and preclinical development candidates.
Evotec has already validated the EVOlution technology against a number of biologically relevant targets including kinases, proteases and protein-protein interactions for therapeutic applications including the Central Nervous System (CNS), oncology, inflammation, metabolic disease and cardiovascular diseases. In these therapeutic areas Evotec is building a pipeline of programmes for early partnering with pharmaceutical and biotechnology companies. In excess of 10 programmes will be initiated in 2007 and activities are ongoing against targets such as Bcl-2/Bcl-xl (oncology), Renin (cardiovascular), BACE (Alzheimer's disease), PI3K (inflammation) and PKC (inflammation). Evotec will seek to partner these programmes once they are in lead optimisation. Evotec is also collaborating with a number of partners using the EVOlution technology to identify novel small molecule leads for their targets and plans to enter into additional such collaborations. Last year the Company partnered its HSP-90 programme in oncology with the Italian biotech company, DAC, a wholly owned subsidiary of Genextra SPA.
Evotec has established a scientific advisory board of eminent scientists for this Innovation Centre to advise on the selection of high quality biological targets for Evotec's pipeline of projects for partnering as well as advising on the development of the programmes and to identify areas to further enhance the technology base. Its members include Professor Sir Ravinder Nath "Tiny" Maini, recently retired as the Director of the Kennedy Research Institute at Imperial College London, Professor Peter Ratcliffe, Nuffield Professor of Medicine and Head of Department at the University of Oxford, Professor David Kerr, Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, University of Oxford, Professor Dame Louise Johnson, David Phillips Professor of Molecular Biophysics at Oxford and Dr Michael Sundstrom, leader of the Structural Genomics Consortium operations in Oxford, UK (for more details see also "Notes to the editor", below).
Jörn Aldag, President & CEO, Evotec commented: "We are excited and delighted that such well regarded scientists have recognised the value of our FBDD technology and have agreed to advise Evotec on the associated research and technology. We strongly believe that this technology will bring innovation to the drug discovery process and will allow us and our clients to develop novel small molecules for a number of therapeutically relevant targets such as enzymes and protein-protein interactions that to date have proven challenging for conventional drug discovery approaches. We have demonstrated that our technology can significantly reduce the timelines traditionally associated with preclinical research and can positively impact programme attrition. In addition, we strongly believe that the implementation of our Innovation Centres will provide innovative solutions to our partners and our internal efforts and will positively address some of the critical issues associated with drug discovery such as attrition, speed and access to novel chemical structures."
Over the next two years Evotec plans to create a number of Innovation Centres in key areas that will bring new innovative solutions for the identification of therapeutic products for the pharmaceutical industry. The Centres will combine existing capabilities and expertise within Evotec with external scientific and technical expertise and investment.
Notes to the editor
EVOlution is a proprietary technology that Evotec utilises to rapidly identify fragment-like molecules that, by their nature, bind to proteins through very weak interactions that can not be detected by traditional methodology. Because they are soluble, low molecular weight compounds are an ideal starting point for novel small molecule drugs and through Evotec's EVOlution technology can be rapidly evolved into lead compounds and preclinical development candidates.
Further details on the FBDD Innovation Centre's scientific advisory board:
Professor Sir Ravinder Nath "Tiny" Maini
Professor Sir Ravinder Nath "Tiny" Maini, is recently retired as the Director of the Kennedy Research Institute at Imperial College, London where he led a team of researchers over a 15 year period looking for new treatments for rheumatoid arthritis. In 2003 he was a co-recipient of the prestigious 2003 Albert Lasker Award for Clinical Medical Research for the discovery of anti-TNF (tumour necrosis factor) as an effective treatment for rheumatoid arthritis and other related diseases. For this work he received a knighthood in 2003.
Professor Peter Ratcliffe
Professor Peter Ratcliffe is Nuffield Professor of Medicine and Head of Department at the University of Oxford. He trained as a Nephologist and was Academic Director of Renal Medicine prior to his appointment to his current position in 2004. He has a broad range of interests in clinical and experimental medicine and has worked extensively on hypoxia signalling pathways, publishing over 150 peer-reviewed manuscripts in this and related fields. In 2002 he was elected Fellow of the Royal Society, and in 2006 member of EMBO.
Professor David Kerr
Professor David Kerr is Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, University of Oxford where he is currently involved in building a new Institute for Cancer Medicine. He has an international reputation for research into and the treatment of colorectal cancer, and is developing new approaches to cancer treatment involving gene therapy. His work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation. He was elected Fellow of the Academy of Medical Sciences in 2000 and appointed Commander of the British Empire in 2002.
Professor Dame Louise Johnson
Dame Louise Johnson is an expert in the field of structural biology. She was appointed as David Phillips Professor of Molecular Biophysics and Professorial Fellow at Corpus Christi, Oxford in 1990. The focus of her current research is on cell cycle regulatory proteins and protein kinases. She was elected as Fellow of the Royal Society in 1990. In 2003 she took up the position of Director of Life Sciences at the Diamond Light Source, the UK's new synchrotron source that will provide new opportunities for both the Life and Physical Sciences.
Dr Michael Sundstrom
Dr Michael Sundstrom leads the Structural Genomics Consortium operations at the site in Oxford, UK. His previous experience includes PhD studies and Post-Doctoral training in protein crystallography and protein biochemistry in Sweden plus solid experience from structural biology/structure based drug design approaches in the pharmaceutical industry with companies such as Pharmacia.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.
In research collaborations, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.
www.evotec.com
Contact:
Dr. David Brister
Chief Business Officer
+44.(0)208.457 5989
david.brister@evotec.com
Anne Hennecke
SVP, Investor Relations &
Corporate Communications
+49.(0)40.56081-286
anne.hennecke@evotec.com
Evotec to Launch its First Innovation Centre for Fragment Based Drug Discovery
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the launch of its Innovation Centre for Fragment Based Drug Discovery ('FBDD'). FBDD offers an alternative approach for identifying novel, small molecule hits (fragments) for a number of biological targets including those that have proved problematic using traditional drug discovery methods as successfully demonstrated by companies such as Astex. Fragments, ideal starting points for rapid evolution to subsequent lead compounds due to their low molecular weight, are difficult to detect due to their weak interactions with protein targets. Evotec has implemented a unique and powerful fragment screening platform, EVOlution, capable of identifying low molecular weight fragments in a biologically relevant environment. The initial step is carried out using Evotec's ultra sensitive screening technologies and its library of 20,000 fragments designed and selected by its medicinal chemists. Combining this screening process with subsequent protein-ligand X-ray crystallography, Evotec's EVOlution technology can identify novel small molecule fragment hits for various, often difficult biological targets in a very short period of time. Leveraging its expertise in medicinal chemistry in combination with its fragment optimisation technology, Evotec can than rapidly progress the fragment programmes to identify novel lead structures and preclinical development candidates.
Evotec has already validated the EVOlution technology against a number of biologically relevant targets including kinases, proteases and protein-protein interactions for therapeutic applications including the Central Nervous System (CNS), oncology, inflammation, metabolic disease and cardiovascular diseases. In these therapeutic areas Evotec is building a pipeline of programmes for early partnering with pharmaceutical and biotechnology companies. In excess of 10 programmes will be initiated in 2007 and activities are ongoing against targets such as Bcl-2/Bcl-xl (oncology), Renin (cardiovascular), BACE (Alzheimer's disease), PI3K (inflammation) and PKC (inflammation). Evotec will seek to partner these programmes once they are in lead optimisation. Evotec is also collaborating with a number of partners using the EVOlution technology to identify novel small molecule leads for their targets and plans to enter into additional such collaborations. Last year the Company partnered its HSP-90 programme in oncology with the Italian biotech company, DAC, a wholly owned subsidiary of Genextra SPA.
Evotec has established a scientific advisory board of eminent scientists for this Innovation Centre to advise on the selection of high quality biological targets for Evotec's pipeline of projects for partnering as well as advising on the development of the programmes and to identify areas to further enhance the technology base. Its members include Professor Sir Ravinder Nath "Tiny" Maini, recently retired as the Director of the Kennedy Research Institute at Imperial College London, Professor Peter Ratcliffe, Nuffield Professor of Medicine and Head of Department at the University of Oxford, Professor David Kerr, Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, University of Oxford, Professor Dame Louise Johnson, David Phillips Professor of Molecular Biophysics at Oxford and Dr Michael Sundstrom, leader of the Structural Genomics Consortium operations in Oxford, UK (for more details see also "Notes to the editor", below).
Jörn Aldag, President & CEO, Evotec commented: "We are excited and delighted that such well regarded scientists have recognised the value of our FBDD technology and have agreed to advise Evotec on the associated research and technology. We strongly believe that this technology will bring innovation to the drug discovery process and will allow us and our clients to develop novel small molecules for a number of therapeutically relevant targets such as enzymes and protein-protein interactions that to date have proven challenging for conventional drug discovery approaches. We have demonstrated that our technology can significantly reduce the timelines traditionally associated with preclinical research and can positively impact programme attrition. In addition, we strongly believe that the implementation of our Innovation Centres will provide innovative solutions to our partners and our internal efforts and will positively address some of the critical issues associated with drug discovery such as attrition, speed and access to novel chemical structures."
Over the next two years Evotec plans to create a number of Innovation Centres in key areas that will bring new innovative solutions for the identification of therapeutic products for the pharmaceutical industry. The Centres will combine existing capabilities and expertise within Evotec with external scientific and technical expertise and investment.
Notes to the editor
EVOlution is a proprietary technology that Evotec utilises to rapidly identify fragment-like molecules that, by their nature, bind to proteins through very weak interactions that can not be detected by traditional methodology. Because they are soluble, low molecular weight compounds are an ideal starting point for novel small molecule drugs and through Evotec's EVOlution technology can be rapidly evolved into lead compounds and preclinical development candidates.
Further details on the FBDD Innovation Centre's scientific advisory board:
Professor Sir Ravinder Nath "Tiny" Maini
Professor Sir Ravinder Nath "Tiny" Maini, is recently retired as the Director of the Kennedy Research Institute at Imperial College, London where he led a team of researchers over a 15 year period looking for new treatments for rheumatoid arthritis. In 2003 he was a co-recipient of the prestigious 2003 Albert Lasker Award for Clinical Medical Research for the discovery of anti-TNF (tumour necrosis factor) as an effective treatment for rheumatoid arthritis and other related diseases. For this work he received a knighthood in 2003.
Professor Peter Ratcliffe
Professor Peter Ratcliffe is Nuffield Professor of Medicine and Head of Department at the University of Oxford. He trained as a Nephologist and was Academic Director of Renal Medicine prior to his appointment to his current position in 2004. He has a broad range of interests in clinical and experimental medicine and has worked extensively on hypoxia signalling pathways, publishing over 150 peer-reviewed manuscripts in this and related fields. In 2002 he was elected Fellow of the Royal Society, and in 2006 member of EMBO.
Professor David Kerr
Professor David Kerr is Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, University of Oxford where he is currently involved in building a new Institute for Cancer Medicine. He has an international reputation for research into and the treatment of colorectal cancer, and is developing new approaches to cancer treatment involving gene therapy. His work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation. He was elected Fellow of the Academy of Medical Sciences in 2000 and appointed Commander of the British Empire in 2002.
Professor Dame Louise Johnson
Dame Louise Johnson is an expert in the field of structural biology. She was appointed as David Phillips Professor of Molecular Biophysics and Professorial Fellow at Corpus Christi, Oxford in 1990. The focus of her current research is on cell cycle regulatory proteins and protein kinases. She was elected as Fellow of the Royal Society in 1990. In 2003 she took up the position of Director of Life Sciences at the Diamond Light Source, the UK's new synchrotron source that will provide new opportunities for both the Life and Physical Sciences.
Dr Michael Sundstrom
Dr Michael Sundstrom leads the Structural Genomics Consortium operations at the site in Oxford, UK. His previous experience includes PhD studies and Post-Doctoral training in protein crystallography and protein biochemistry in Sweden plus solid experience from structural biology/structure based drug design approaches in the pharmaceutical industry with companies such as Pharmacia.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.
In research collaborations, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.
www.evotec.com
Contact:
Dr. David Brister
Chief Business Officer
+44.(0)208.457 5989
david.brister@evotec.com
Anne Hennecke
SVP, Investor Relations &
Corporate Communications
+49.(0)40.56081-286
anne.hennecke@evotec.com
Antwort auf Beitrag Nr.: 29.358.101 von luckylost am 17.05.07 15:41:34Stimme ich dir zu!
Heute sich es danach aus, als würde wieder ein Ausbruchsversuch kommen. Mein Gefühl täuschte mich bisher fast NIE.
Heute sich es danach aus, als würde wieder ein Ausbruchsversuch kommen. Mein Gefühl täuschte mich bisher fast NIE.
Durchsuchen
17:50 Uhr · wO Newsflash · Carl Zeiss Meditec |
10:30 Uhr · Sharedeals · Evotec |
30.05.24 · BörsenNEWS.de · Evotec |
30.05.24 · dpa-AFX · Agilent Technologies |
30.05.24 · dpa-AFX · Agilent Technologies |
30.05.24 · wO Newsflash · Evotec |
30.05.24 · wO Newsflash · Evotec |
